Nanobiotix S.A.
NNBXF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$430.11M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $430.11 Million |
|---|---|
| Enterprise Value | $461.99 Million |
| Earnings per Share | $-1.44 |
| Beta | 0 |
| Outstanding Shares | 47,265,189 |
Return
| Return on Equity | 314.58% |
|---|---|
| Return on Assets | -81.83% |
| Return on Invested Capital | -165.35% |
Valuation & Multiples
| P/E Ratio | -23.44 |
|---|---|
| PEG | -4.3 |
| Price to Sales | - |
| Price to Book Ratio | -9.1 |
| Enterprise Value to Revenue | 37.15 |
| Enterprise Value to EBIT | -6.59 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | -4.28 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Nanobiotix
89 employees
CEO: Laurent Levy
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of cry...